Abstract P6-12-14: Quality of life and ability to work in patients at different disease stages of HER2+ breast cancer

M Verrill, A Wardley, J Retzler, A B Smith, D Mcnicol, S Dando, I Tran, I Leslie, P Schmid

Research output: Contribution to journalMeeting Abstract

Abstract

OBJECTIVES: Health-related quality of life (HRQoL) and ability to work in patients treated for HER2+ early breast cancer (EBC) are poorly understood. This study compared HRQoL and ability to work in 3 HER2+ patient cohorts: EBC during adjuvant treatment, EBC after treatment, and metastatic disease (MBC). METHODS: A cross-sectional observational cohort study of 299 female consenting patients with HER2+BC, from 14 UK secondary care centres. Group1 (n=89): receiving targeted HER2 therapy±chemotherapy for EBC; Group2 (n=108): in follow up post-targeted treatment for eBC; Group3 (n=102): MBC on treatment. Data collected between Dec 2016-Mar 2017: HRQoL, demographic and employment status data collected via patient-reported questionnaires (including EQ-5D-5L and Functional Assessment of Cancer Therapy [FACT-B]); clinical data collected from medical records. Inter-group differences were assessed using univariate Analysis of variance (ANOVA) and chi-square tests as appropriate. [NCT03099200]. RESULTS: Table1 shows patient demographics, disease characteristics, employment status, and EQ-5D-5L scores. Group1 and Group2 patients did not differ in overall health utility or visual analogue scale (VAS) scores. However, Group3 patients reported significantly poorer health utility than Group1 (p<0.02) and Group2 (p<0.001), and significantly worse VAS scores than Group2 (p<0.001). Significantly fewer Group2 patients and more Group3 patients were unable to work (p<0.003), and fewer Group3 patients were employed than expected (by chi-square, p<0.003). CONCLUSIONS: HRQoL in patients with EBC was similar whether on or off treatment, and better than those with MBC. HRQoL scores reported on the generic EQ-5D will be compared with those from the disease-specific FACT-B. A smaller proportion of patients with MBC were employed compared to the EBC groups, reflecting the impact of advanced disease. Fewer patients with EBC reported being unable to work than we expected, suggesting these patients maintain function
LanguageEnglish
PagesP6-12-14
Number of pages1
JournalCancer Research
Volume78
Issue number4 Supplement
DOIs
Publication statusPublished - 15 Feb 2018
Externally publishedYes
Event40th Annual San Antonio Breast Cancer Symposium - San Antonio, Philadelphia, United States
Duration: 5 Dec 20179 Dec 2017
Conference number: 40
https://www.sabcs.org/Past-Meetings#SABCS2017 (Link to Symposium Information)

Fingerprint

Quality of Life
Breast Neoplasms
Visual Analog Scale
Therapeutics
Secondary Care Centers
Demography
Mars
Health
Chi-Square Distribution
Medical Records
Observational Studies
Analysis of Variance
Cohort Studies
Drug Therapy

Cite this

Verrill, M ; Wardley, A ; Retzler, J ; Smith, A B ; Mcnicol, D ; Dando, S ; Tran, I ; Leslie, I ; Schmid, P. / Abstract P6-12-14: Quality of life and ability to work in patients at different disease stages of HER2+ breast cancer. In: Cancer Research. 2018 ; Vol. 78, No. 4 Supplement. pp. P6-12-14.
@article{a170e37b31314cec91d6ce6ebe1e1507,
title = "Abstract P6-12-14: Quality of life and ability to work in patients at different disease stages of HER2+ breast cancer",
abstract = "OBJECTIVES: Health-related quality of life (HRQoL) and ability to work in patients treated for HER2+ early breast cancer (EBC) are poorly understood. This study compared HRQoL and ability to work in 3 HER2+ patient cohorts: EBC during adjuvant treatment, EBC after treatment, and metastatic disease (MBC). METHODS: A cross-sectional observational cohort study of 299 female consenting patients with HER2+BC, from 14 UK secondary care centres. Group1 (n=89): receiving targeted HER2 therapy±chemotherapy for EBC; Group2 (n=108): in follow up post-targeted treatment for eBC; Group3 (n=102): MBC on treatment. Data collected between Dec 2016-Mar 2017: HRQoL, demographic and employment status data collected via patient-reported questionnaires (including EQ-5D-5L and Functional Assessment of Cancer Therapy [FACT-B]); clinical data collected from medical records. Inter-group differences were assessed using univariate Analysis of variance (ANOVA) and chi-square tests as appropriate. [NCT03099200]. RESULTS: Table1 shows patient demographics, disease characteristics, employment status, and EQ-5D-5L scores. Group1 and Group2 patients did not differ in overall health utility or visual analogue scale (VAS) scores. However, Group3 patients reported significantly poorer health utility than Group1 (p<0.02) and Group2 (p<0.001), and significantly worse VAS scores than Group2 (p<0.001). Significantly fewer Group2 patients and more Group3 patients were unable to work (p<0.003), and fewer Group3 patients were employed than expected (by chi-square, p<0.003). CONCLUSIONS: HRQoL in patients with EBC was similar whether on or off treatment, and better than those with MBC. HRQoL scores reported on the generic EQ-5D will be compared with those from the disease-specific FACT-B. A smaller proportion of patients with MBC were employed compared to the EBC groups, reflecting the impact of advanced disease. Fewer patients with EBC reported being unable to work than we expected, suggesting these patients maintain function",
author = "M Verrill and A Wardley and J Retzler and Smith, {A B} and D Mcnicol and S Dando and I Tran and I Leslie and P Schmid",
year = "2018",
month = "2",
day = "15",
doi = "10.1158/1538-7445.SABCS17-P6-12-14",
language = "English",
volume = "78",
pages = "P6--12--14",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "4 Supplement",

}

Verrill, M, Wardley, A, Retzler, J, Smith, AB, Mcnicol, D, Dando, S, Tran, I, Leslie, I & Schmid, P 2018, 'Abstract P6-12-14: Quality of life and ability to work in patients at different disease stages of HER2+ breast cancer' Cancer Research, vol. 78, no. 4 Supplement, pp. P6-12-14. https://doi.org/10.1158/1538-7445.SABCS17-P6-12-14

Abstract P6-12-14: Quality of life and ability to work in patients at different disease stages of HER2+ breast cancer. / Verrill, M; Wardley, A; Retzler, J; Smith, A B; Mcnicol, D; Dando, S; Tran, I; Leslie, I; Schmid, P.

In: Cancer Research, Vol. 78, No. 4 Supplement, 15.02.2018, p. P6-12-14.

Research output: Contribution to journalMeeting Abstract

TY - JOUR

T1 - Abstract P6-12-14: Quality of life and ability to work in patients at different disease stages of HER2+ breast cancer

AU - Verrill,M

AU - Wardley,A

AU - Retzler,J

AU - Smith,A B

AU - Mcnicol,D

AU - Dando,S

AU - Tran,I

AU - Leslie,I

AU - Schmid,P

PY - 2018/2/15

Y1 - 2018/2/15

N2 - OBJECTIVES: Health-related quality of life (HRQoL) and ability to work in patients treated for HER2+ early breast cancer (EBC) are poorly understood. This study compared HRQoL and ability to work in 3 HER2+ patient cohorts: EBC during adjuvant treatment, EBC after treatment, and metastatic disease (MBC). METHODS: A cross-sectional observational cohort study of 299 female consenting patients with HER2+BC, from 14 UK secondary care centres. Group1 (n=89): receiving targeted HER2 therapy±chemotherapy for EBC; Group2 (n=108): in follow up post-targeted treatment for eBC; Group3 (n=102): MBC on treatment. Data collected between Dec 2016-Mar 2017: HRQoL, demographic and employment status data collected via patient-reported questionnaires (including EQ-5D-5L and Functional Assessment of Cancer Therapy [FACT-B]); clinical data collected from medical records. Inter-group differences were assessed using univariate Analysis of variance (ANOVA) and chi-square tests as appropriate. [NCT03099200]. RESULTS: Table1 shows patient demographics, disease characteristics, employment status, and EQ-5D-5L scores. Group1 and Group2 patients did not differ in overall health utility or visual analogue scale (VAS) scores. However, Group3 patients reported significantly poorer health utility than Group1 (p<0.02) and Group2 (p<0.001), and significantly worse VAS scores than Group2 (p<0.001). Significantly fewer Group2 patients and more Group3 patients were unable to work (p<0.003), and fewer Group3 patients were employed than expected (by chi-square, p<0.003). CONCLUSIONS: HRQoL in patients with EBC was similar whether on or off treatment, and better than those with MBC. HRQoL scores reported on the generic EQ-5D will be compared with those from the disease-specific FACT-B. A smaller proportion of patients with MBC were employed compared to the EBC groups, reflecting the impact of advanced disease. Fewer patients with EBC reported being unable to work than we expected, suggesting these patients maintain function

AB - OBJECTIVES: Health-related quality of life (HRQoL) and ability to work in patients treated for HER2+ early breast cancer (EBC) are poorly understood. This study compared HRQoL and ability to work in 3 HER2+ patient cohorts: EBC during adjuvant treatment, EBC after treatment, and metastatic disease (MBC). METHODS: A cross-sectional observational cohort study of 299 female consenting patients with HER2+BC, from 14 UK secondary care centres. Group1 (n=89): receiving targeted HER2 therapy±chemotherapy for EBC; Group2 (n=108): in follow up post-targeted treatment for eBC; Group3 (n=102): MBC on treatment. Data collected between Dec 2016-Mar 2017: HRQoL, demographic and employment status data collected via patient-reported questionnaires (including EQ-5D-5L and Functional Assessment of Cancer Therapy [FACT-B]); clinical data collected from medical records. Inter-group differences were assessed using univariate Analysis of variance (ANOVA) and chi-square tests as appropriate. [NCT03099200]. RESULTS: Table1 shows patient demographics, disease characteristics, employment status, and EQ-5D-5L scores. Group1 and Group2 patients did not differ in overall health utility or visual analogue scale (VAS) scores. However, Group3 patients reported significantly poorer health utility than Group1 (p<0.02) and Group2 (p<0.001), and significantly worse VAS scores than Group2 (p<0.001). Significantly fewer Group2 patients and more Group3 patients were unable to work (p<0.003), and fewer Group3 patients were employed than expected (by chi-square, p<0.003). CONCLUSIONS: HRQoL in patients with EBC was similar whether on or off treatment, and better than those with MBC. HRQoL scores reported on the generic EQ-5D will be compared with those from the disease-specific FACT-B. A smaller proportion of patients with MBC were employed compared to the EBC groups, reflecting the impact of advanced disease. Fewer patients with EBC reported being unable to work than we expected, suggesting these patients maintain function

U2 - 10.1158/1538-7445.SABCS17-P6-12-14

DO - 10.1158/1538-7445.SABCS17-P6-12-14

M3 - Meeting Abstract

VL - 78

SP - P6-12-14

JO - Journal of Cancer Research

T2 - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 4 Supplement

ER -